APA (7th ed.) Citation

Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., . . . San Miguel, J. (2009). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. British journal of haematology, 144(6), . https://doi.org/10.1111/j.1365-2141.2008.07573.x

Chicago Style (17th ed.) Citation

Richardson, Paul G., et al. "Reversibility of Symptomatic Peripheral Neuropathy with Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-modification Guideline." British Journal of Haematology 144, no. 6 (2009). https://doi.org/10.1111/j.1365-2141.2008.07573.x.

MLA (9th ed.) Citation

Richardson, Paul G., et al. "Reversibility of Symptomatic Peripheral Neuropathy with Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-modification Guideline." British Journal of Haematology, vol. 144, no. 6, 2009, https://doi.org/10.1111/j.1365-2141.2008.07573.x.